Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(6.23) per share which beat the analyst consensus estimate of $(8.10) by 23.09 percent. This is a 97.38 percent increase over losses of $(237.60) per share from the same period last year.